MHS PHARMACY BENEFIT

ADULT (≥18 YEARS OF AGE) GROWTH HORMONE PRIOR AUTHORIZATION REQUEST FORM

MHS

429 N. Pennsylvania St. Suite 109 Indianapolis, IN, 46204-1208 Phone: (877) 647-4848 Fax: (866) 399-0929

Today's Date



Patient's Medicaid #		Date of Birth	/ / /
Patient's Name		Prescriber's Name	
Prescriber's IN License #		Specialty	
Prescriber's NPI #		Prescriber's Signa	ture
Return Fax #		Return Phone #	
Check box if requesting retro-active PA		Date(s) of service retro-active eligibil	
		•	
vice 30 calendar days or less and going	forward).		Treatment Duration
vice 30 calendar days or less and going	forward).	osage	Treatment Duration
gibility timelines) with dates of service priorice 30 calendar days or less and going Requested Medication and Streng	forward).		Treatment Duration
vice 30 calendar days or less and going	th Do		Treatment Duration

0724.PH.P.FO.4 8/24

07.01.2024 Page 1

	•	4 41	ormone deficiency		
	_		equired for diagnosis	_	-
			olicable testing suppo	rting the diagnosis	
		the following: r a preferred agent			
	•	•	ent with a product-spe	eific indication:	
	List indication		ni wiin a product-spe	cinc maication.	
			on-preferred agent over	er preferred agent	based on the following
	nedical justifi		ni profortou agont ove	or profession agosti	bacca on the fellowing
	noaioai jaoiin	odion.			
_					
□ Diagnosis	s of HIV-asso	ociated wasting or ca	chexia (Serostim only	<i>(</i>)	
*The foll	owing docu		equired for diagnosis		ated wasting or
	exia"				
		measurement of lean ric impedance analys		XA (dual energy X	-ray absorptiometry) or
	`		ght loss of >10% of ba	aseline total body v	veight OR body cell
		for initial approval	,	,	3
Member'	s current AID	OS/HIV anti-retroviral	regimen:		
			•		
			lowing (include trial da	•	-
for failure	e): \square Dron	abinol	Anabolic Steroids [None Other Other Other	(please explain)
expanding intrac	ranial lesions re that this n h hormone t	s or tumors prior to in member does not hatherapy.	itiating growth hormone itiating growth hormone itiating growth hormone itiating intractions are expanding intractions.	ne therapy Ye	ed all necessary
Please complete	the following	g:			
Current	:	height:	(inches)	weight:	(lbs)
3 month	s prior:	height:	(inches)	weight:	(lbs)
3 month 6 month	-	-	(inches)	-	
	-	-		-	
6 month	s prior:	height:		-	
6 month SOMATROPIN A	as prior: AGENTS – R	height:Reauthorization	(inches)	weight:	
6 month SOMATROPIN A Please select of	AGENTS - R	height:Reauthorization lowing: ly been transitioned f		weight:	
SOMATROPIN A Please select of Member Please s	AGENTS – Rone of the following previous select one of	height:Reauthorization lowing: sly been transitioned f the following:	(inches)	weight:	
SOMATROPIN A Please select or	AGENTS – Rene of the follows previous select one of Request is for	height:Reauthorization lowing: sly been transitioned f the following: r a preferred agent	(inches)	weight:hormone therapy	
SOMATROPIN A Please select or Member I Please s	AGENTS – Rone of the following previous delect one of Request is for Request is f	height:Reauthorization lowing: sly been transitioned f the following: r a preferred agent	(inches) from pediatric growthent with a product-spe	weight:hormone therapy	

07.01.2024 Page 2

	medical justific		on-preferred agent ov	er preferred agent t	pased on the following
Please	e select one of t Request is for Request is for	he following: a preferred agent a non-preferred ag	normone deficiency an ent with a product-spe	ecific indication:	vth hormone
		uld like to utilize a n			pased on the following
☐ Membe therapy •	y Member's cur Member has o	rent AIDS/HIV anti-	ed wasting or cachexia retroviral regimen: crease in total body we		
I,testing to ensinitiating grow	ure that this m	or tumors prior to i	nitiating growth hormo	ne therapy Yes	ed all necessary
Please comple	te the following	:			
Curre			(inches)	weight:	(lbs)
	ths prior:		(inches)	•	,
	ths prior:	-	(inches)	-	
•) – Initial Authoriz			
*The following	g documentati	-	☐ Yes ☐ No I for diagnosis of "ac testing supporting the	-	ne deficiency"
Member is 18 y	years of age or	older ☐ Yes ☐ N	10		
☐ Tria	one of the follow al and failure of at products triale	ALL preferred som	atropin products		

07.01.2024 Page 3

 Prescriber would like to utilize a Sogroya (somapacitan) over ALL preferred somatropin agents based on the following medical justification:
based on the following medical justification.
Prescriber attests that they have performed all necessary testing to ensure there are no expanding intracranial
lesions or tumors prior to initiating growth hormone therapy \square Yes \square No
I,hereby attest that I have performed all necessary testing to ensure that this member does not have expanding intracranial lesions or tumors prior to initiating growth hormone therapy.
Proceribor Signaturo
Frescriber Signature.
Prescriber Signature:
SOGROYA (SOMAPACITAN) – Reauthorization
SOGROYA (SOMAPACITAN) – Reauthorization Prescriber attests that they are continuing to monitor the member for intracranial tumor recurrence, progression of underlying disease, or malignant transformation of skin lesions, if appropriate Yes No hereby attest that I have performed all necessary
SOGROYA (SOMAPACITAN) – Reauthorization Prescriber attests that they are continuing to monitor the member for intracranial tumor recurrence, progression of underlying disease, or malignant transformation of skin lesions, if appropriate Yes No

CONFIDENTIAL INFORMATION

This facsimile transmission (and attachments) may contain protected health information from the Indiana Health Coverage Programs (IHCP), which is intended only for the use of the individual or entity named in this transmission sheet. Any unintended recipient is hereby notified that the information is privileged and confidential, and any use, disclosure, or reproduction of this information is prohibited.

Page 4 07.01.2024